Reflex Human Immunodeficiency Virus (HIV) Type 1 RNA Testing Enables Timely Differentiation of False-Positive Results From Acute HIV Infection.

"Potential conflicts of interest. M. C. M. has served on an advisory board for Gilead Sciences, Inc. J. S. and D. P. report grant support from Gilead Sciences, Inc. All other authors report no potential conflicts."

"Financial support. The Expanded HIV Testing and Linkage to Care Program is funded by the Health Resources and Services Administration (HRSA) through the Chicago Department of Public Health. Additional support is provided through the Gilead Sciences Frontlines of Communities in the United States (FOCUS) program. FOCUS funding supports HIV, hepatitis C virus, and hepatitis B virus screening and linkage to the first medical appointment after diagnosis; FOCUS funding does not support any activities beyond the first medical appointment and is agnostic to how FOCUS partners handle subsequent patient care and treatment. M. C. M. was supported by the National Institutes of Health (award number K23MH118969). K. A. S. is supported by the National Institutes of Health (award number K23AI166277). Financial support ."